EYPT Stock Analysis: Buy, Sell, or Hold?
EYPT - EyePoint Pharmaceuticals, Inc. Common Stock
$14.38
0.65 (4.73%)
▲
5d:
+19.04%
30d:
+12.52%
90d:
+12.08%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.1/10
Get Alerted When EYPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: EYPT is 7.1% above its trading range ($13.43). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: EYPT is 7.1% above its trading range ($13.43). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: EYPT is currently trading at $14.38, which is considered extended relative to its 30-day fair value range of $12.00 to $13.43.
Technical Outlook: Technically, EYPT is in a downtrend. Immediate support is located at $11.29, while resistance sits at $14.84. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: EYPT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $37.00 (+157.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EYPT is in a downtrend. Immediate support is located at $11.29, while resistance sits at $14.84. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: EYPT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $37.00 (+157.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.00 -
$13.43
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+7.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 157.3% below Wall St target ($37.00)
- CAUTION: Extended 7.1% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$12.00 -
$13.43
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.30
Resistance Level
$14.84
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.10
Wall Street Target
$37.00
(+157.3%)
Revenue Growth (YoY)
161.7%
Share & Embed Analysis
Last updated: June 23, 2026 10:09 PM ET
Data refreshes hourly during market hours. Next update: 11:09 PM
Data refreshes hourly during market hours. Next update: 11:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EYPT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ramiro Ribeiro
SELL
2437 shares
2026-04-17
Jay S Duker
BUY
1500 shares
2026-03-16
Ramiro Ribeiro
SELL
42544 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
